Folic acid (also known as vitamin B9, vitamin Bc or folacin) and folate (the naturally occurring form), as well as pteroyl-L-glutamic acid, pteroyl-L-glutamate, and pteroylmonoglutamic acid are forms of the water-soluble vitamin B9. Folic acid is itself not biologically active, but its biological importance is due to tetrahydrofolate and other derivatives after its conversion to dihydrofolic acid in the liver.
Vitamin B9 (folic acid and folate inclusive) is essential to numerous bodily functions. The human body needs folate to synthesize DNA, repair DNA, and methylate DNA as well as to act as a cofactor in biological reactions involving folate. It is especially important in aiding rapid cell division and growth, such as in infancy and pregnancy, as well as in "feeding" some cancers. While a normal diet also high in natural folates may decrease the risk of cancer, there is diverse evidence that high folate intake from supplementation may actually promote some cancers as well as precancerous tumors and lesions. Children and adults both require folic acid to produce healthy red blood cells and prevent anemia.
Folate and folic acid derive their names from the Latin word ''folium'' (which means "leaf"). Leafy vegetables are a principal source, although in Western diets fortified cereals and bread may be a larger dietary source.
A lack of dietary folic acid leads to folate deficiency which is uncommon in normal Western diets. Failures to replenish one's folates might not manifest themselves as folate deficiency for 4 months because a healthy individual has about 500–20,000 µg of folate in body stores. This deficiency can result in many health problems, the most notable one being neural tube defects in developing embryos. Common symptoms of folate deficiency include diarrhea, macrocytic anemia with weakness or shortness of breath, nerve damage with weakness and limb numbness (peripheral neuropathy), pregnancy complications, mental confusion, forgetfulness or other cognitive declines, mental depression, sore or swollen tongue, peptic or mouth ulcers, headaches, heart palpitations, irritability, and behavioral disorders. Low levels of folate can also lead to homocysteine accumulation. DNA synthesis and repair are impaired and this could lead to cancer development. Supplementation in patients with ischaemic heart disease may also lead to increased rates of cancer.
+National Institutes of Health Nutritional Requirements (µg per day) | ||||||||
! Age | Reference Daily Intake>RDI) | Dietary Reference Intake#Current recommendations>UL) | ! Adults (RDI) | ! Adults (UL) | ! Pregnant women (RDI) | ! Pregnant women (UL) | ! Lactating women (RDI) | ! Lactating women (UL) |
0–6 months | 65 | None set | ||||||
7–12 months | 80 | None set | ||||||
1–3 years | ||||||||
4–8 years | ||||||||
9–13 years | ||||||||
14–18 | ||||||||
19+ |
The Dietary Reference Intake (DRIs) were developed by the United States National Academy of Sciences to set reference values for planning and assessing nutrient intake for healthy people. DRIs incorporate two reference values, the Reference Daily Intake (RDI, the daily intake level that is adequate for 97–98% of the population in the United States where the standards were set) and tolerable upper intake levels (UL, the highest level of intake which is known to avoid toxicity). The UL for folate refers to only synthetic folate, as no health risks have been associated with high intake of folate from food sources.
Moderate amounts:
Certain fruits (orange juice, canned pineapple juice, cantaloupe, honeydew melon, grapefruit juice, banana, raspberry, grapefruit and strawberry) and vegetables (beets, corn, tomato juice, vegetable juice, broccoli, brussels sprouts, romaine lettuce and bok choy), beer.
A table of selected food sources of folate and folic acid can be found at the USDA National Nutrient Database for Standard Reference. Folic acid is added to grain products in many countries, and, in these countries, fortified products make up a significant source of the population's folic acid intake. Because of the difference in bioavailability between supplemented folic acid and the different forms of folate found in food, the dietary folate equivalent (DFE) system was established. 1 DFE is defined as 1 μg of dietary folate, or 0.6 μg of folic acid supplement. This is reduced to 0.5 μg of folic acid if the supplement is taken on an empty stomach.
Folic acid naturally found in food is susceptible to high heat and ultraviolet light, and is soluble in water. It is heat-labile in acidic environments and may also be subject to oxidation.
Some meal replacement products do not meet the folate requirements as specified by the RDAs.
In the form of a series of tetrahydrofolate (THF) compounds, folate derivatives are substrates in a number of single-carbon-transfer reactions, and also are involved in the synthesis of dTMP (2′-deoxythymidine-5′-phosphate) from dUMP (2′-deoxyuridine-5′-phosphate). It is a substrate for an important reaction that involves vitamin B12 and it is necessary for the synthesis of DNA, and so required for all dividing cells.
The pathway leading to the formation of tetrahydrofolate (FH4) begins when folate (F) is reduced to dihydrofolate (DHF) (FH2), which is then reduced to THF. Dihydrofolate reductase catalyses the last step. Vitamin B3 in the form of NADPH is a necessary cofactor for both steps of the synthesis.
Methylene-THF (CH2FH4) is formed from THF by the addition of methylene groups from one of three carbon donors: formaldehyde, serine, or glycine. Methyl tetrahydrofolate (CH3-THF) can be made from methylene-THF by reduction of the methylene group with NADPH. It is important to note that Vitamin B12 is the only acceptor of methyl-THF. There is also only one acceptor for methyl-B12, which is homocysteine in a reaction catalyzed by homocysteine methyltransferase. This is important because a defect in homocysteine methyltransferase or a deficiency of B12 can lead to a methyl-trap of THF and a subsequent deficiency. Thus, a deficiency in B12 can generate a large pool of methyl-THF that is unable to undergo reactions and will mimic folate deficiency. Another form of THF, formyl-THF or folinic acid results from oxidation of methylene-THF or is formed from formate donating formyl group to THF. Finally, histidine can donate a single carbon to THF to form methenyl-THF.
In other words: : folate → dihydrofolate → tetrahydrofolate ↔ methylene-THF → methyl-THF
Valproic acid, one of the most commonly prescribed anticonvulsants that is also used to treat certain psychological conditions, is a known inhibitor of folic acid, and as such, has been shown to cause neural tube defects and cases of spina bifida and cognitive impairment in the newborn. Because of this considerable risk, those mothers who must continue to use valproic acid or its derivatives during pregnancy to control their condition (as opposed to stopping the drug or switching to another drug or to a lesser dose) should take folic acid supplements under the direction and guidance of their health care providers.
The National Health and Nutrition Examination Survey (NHANES III 1988–91) and the Continuing Survey of Food Intakes by Individuals (1994–96 CSFII) indicated most adults did not consume adequate folate. However, the folic acid fortification program in the United States has increased folic acid content of commonly eaten foods such as cereals and grains, and as a result, diets of most adults now provide recommended amounts of folate equivalents.
Folic acid may also reduce chromosomal defects in sperm. A benefit is indicated even for more than 700 mcg folate per day, which, though below the tolerable upper intake levels of 1,000 µg/day, was 1.8 times the recommended dietary allowance.
As of 2006, studies have shown giving folic acid to reduce levels of homocysteine does not result in clinical benefit. One of these studies suggests folic acid in combination with B12 may even increase some cardiovascular risks.
However, a 2005 study found 5 mg of folate daily over a three-week period reduced pulse pressure by 4.7 mmHg compared with a placebo, and concluded folic acid is a safe and effective supplement that targets large artery stiffness and may prevent isolated systolic hypertension.
Also, as a result of new research, "heart experts" at Johns Hopkins Medical Center reported in March 2008 in favour of therapeutic folate, although they cautioned that it is premature for people to begin to self-medicate by taking high doses of folic acid."
Hyperhomocysteinemia is a predictor of cardiovascular disease and hypertension among children and folic acid is a safe and effective supplement because it reduces serum homocysteine levels as well as systolic and diastolic blood pressure, thus preventing cardiovascular disease in children.
Folic acid supplements may improve the integrity of the vascular endothelium. Folic acid supplements consumed before and during pregnancy may reduce the risk of heart defects in infants, and may reduce the risk for children to develop metabolic syndrome. That may, however, worsen the outcomes in patients with cardiovascular disease such as angina and myocardial infarction.
The association between folate and cancer appears to be complex and mixed. There are theoretical reasons that folate may help prevent cancer, and a meta-analysis published in 2010 failed to find a statistically significant cancer risk due to folic acid treatments, but a 1995 study found supplementation ''increases'' rates of cancer.
Some investigations have proposed good levels of folic acid may be related to lower risk of esophageal, stomach, and ovarian cancers, but the benefits of folic acid against cancer may depend on when it is taken and on individual conditions. In addition, folic acid may not be helpful, and could even be damaging, in people already suffering from cancer or from a precancerous condition. Likewise, it has been suggested excess folate may promote tumor initiation. Folate has shown to play a dual role in cancer development; ''low'' folate intake protects against early carcinogenesis, and ''high'' folate intake promotes advanced carcinogenesis. Therefore, public health recommendations should be careful not to encourage too much folate intake.
Diets high in folate are associated with decreased risk of colorectal cancer; some studies show the association is stronger for folate from foods alone than for folate from foods and supplements, while other studies find that folate from supplements is more effective due to greater bioavailability. A 2007 randomized clinical trial found folate supplements did not reduce the risk of colorectal adenomas, and in fact increase the presence of advanced lesions and adenoma multiplicity. Colorectal cancer is the most studied type of cancer in relation to folate and one carbon metabolism. For example, folic acid supplement intake increased advanced colorectal cancer development by 67% in a 14-year European research study involving 520,000 men.
A 2006 prospective study of 81,922 Swedish adults found diets great in folate from foods, but not from supplements, were associated with a reduced risk of pancreatic cancer.
Most epidemiologic studies suggest diets high in folate are associated with decreased risk of breast cancer, but results are not uniformly consistent. One broad cancer screening trial reported a potential harmful effect of much folate intake on breast cancer risk, suggesting routine folate supplementation should not be recommended as a breast cancer preventive, but a 2007 Swedish prospective study found much folate intake was associated with a lower incidence of postmenopausal breast cancer. A 2008 study has shown no significant effect of folic acid on overall risk of total invasive cancer or breast cancer among women. Folate intake may not have any effect on the risk of breast cancer but may have an effect for women who consume at least 15 g/d of alcohol. Folate intake of more than 300 µg/d may reduce the risk of breast cancer in women who consume alcohol.
Most research studies associate high dietary folate intake with a reduced risk of prostate cancer; however, in men, folic acid supplementation appears to double the risk of prostate cancer. Recently, a clinical trial showed daily supplementation of 1 mg of folic acid increased the risk of prostate cancer, while dietary and plasma folate levels among vitamin nonusers actually decreased the risk of prostate cancer. A Finnish study consisting of 29,133 older male smokers observed prostate cancer risk had no relationship with serum folate levels.
The reason high levels of folic acid may increase cancer is because of its role in nucleotide synthesis (proliferating neoplastic cells need this and folate receptors are increased in cancers). Folate's role in DNA methylation is important in prostate cancer. Unmetabolized folic acid is associated with a reduction in natural killer cell cytotoxicity, which reduces the immune system's ability to defend against malignant cells. However, the study also showed dietary baseline intake of folate may have an inverse relationship to prostate cancer occurrence.
Although the relationship between folate and prostate cancer is not yet clear, suicide gene studies show a target vector for folate to prostate and nasopharyngeal cancer cells. Growth of tumor cells is significantly inhibited when a folate-linked nanoparticle is injected intratumorally. The mechanism might be the interference of transfection and communication failures of intracellular gap junctions.
The cancer drug methotrexate is designed to inhibit the metabolism of folic acid. Folic acid may interact unexpectedly with the cancer drug fluorouracil. The exact mechanism of interaction is unknown.
The low dihydrofolate reductase activity in the liver of humans compared to other animals and so the low conversion of folic acid into its active derivatives might be due to the control of this enzyme by transcription factors, such as E2F-1 involved in cell proliferation. It has been suggested "the low level of DHFR, and the other proteins under the control of E2F-1, in humans may have evolved to hinder the development of cancer. If this is the case, other animals with slow tissue turnover rates, possibly related to long life span, might also have low DHFR activity."
Folic acid supplements prevent mistakes (inserting uracils into the DNA, for example) from occurring during DNA replication and repair. This is a proposed mechanism for folic acid's protection against colorectal cancer.
Folic acid supplements stimulate the PI3k/Akt signaling cascade, which leads to improved cell survival, but this could be beneficial or harmful for the body because cancer cells may use this pathway to survive. Folic acid may also reduce the levels of PTEN (a tumor suppressor gene), making this relationship even more controversial.
Additionally, low amounts of folate may increase lung cancer risk, as evidenced in an epidemiological study that have suggested a relationship between low folate status and lung cancer. One such study suggested that folic acid combined with vitamin B12 reduced evidence of atypical bronchial squamous metaplasia in smokers.
Folinic acid, under the drug name leucovorin,a form of folate (formyl-THF), can help "rescue" or reverse the toxic effects of methotrexate. Folinic acid is ''not'' the same as folic acid. Folic acid supplements have little established role in cancer chemotherapy. There have been cases of severe adverse effects of accidental substitution of folic acid for folinic acid in patients receiving methotrexate cancer chemotherapy. It is important for anyone receiving methotrexate to follow medical advice on the use of folic or folinic acid supplements. The supplement of folinic acid in patients undergoing methotrexate treatment is to give cells dividing less rapidly enough folate to maintain normal cell functions. The amount of folate given will be depleted by rapidly dividing cells (cancer) very fast and so will not negate the effects of methotrexate.
In fact, to date the evidence such masking actually occurs is scarce, and there is no evidence folic acid fortification in Canada or the U.S. has increased the prevalence of vitamin B12 deficiency or its consequences. However, one recent study has demonstrated high folic or folate levels, when combined with low B12 levels, are associated with significant cognitive impairment among the elderly.
In any case, it is important for older adults to be aware of the relationship between folic acid and vitamin B12, because they are at greater risk of having a B12 deficiency. For this reason, a physician may wish to check the vitamin B12 status of patients 50 years of age or older before prescribing them a supplement that contains folic acid.
Research suggests high levels of folic acid can interfere with some antimalarial treatments.
A 10,000-patient study at Tufts University in 2007 concluded excess folic acid worsens the effects of B12 deficiency and, in fact, may affect the absorption of B12.
A study at the University of Adelaide concluded the intake of folic acid supplements during late pregnancy increases the risk of babies developing childhood asthma by 30%, although researchers emphasized that their finding did not contradict recommendations to supplement folic acid in first trimester, when no additional risk was found.
This has led to the introduction in many countries of ''fortification'', where folic acid is added to flour with the intention of benefiting all from the associated rise in blood folate levels. This is controversial, with issues having been raised concerning individual liberty , and the masking effect of folate fortification on pernicious anaemia (vitamin B12 deficiency). However, several western countries now fortify their flour, along with a number of Middle Eastern countries and Indonesia. Mongolia and a number of former Soviet republics are among those having widespread voluntary fortification; about five more countries (including Morocco, the first African country) have agreed, but not yet implemented, fortification. To date, no EU country has yet mandated fortification.
Folates can be produced by engineering ''Lactococcus lactis'' strains using a rodent depletion-repletion bioassay, and the bioavailabilities of these folates are comparable with those of commercial folic acid currently being used for food fortification. These engineered folates can potentially help alleviate the effects of folate deficiency in the diet. Hematologic studies show an improvement in megaloblastic anemia after the addition of ''L. lactis'' strains; this again suggests lactic acid bacteria can potentially reverse some of the harm done by folate deficiency by acting as an essential, bioavailable vitamin.
Australia and New Zealand have jointly agreed to fortification though the Food Standards Australia New Zealand. Australia will fortify all flour from 18 September 2009. Although the food standard covers both Australia and New Zealand, an Australian government official has stated it is up to New Zealand to decide whether to implement it there, and they will watch with interest.
The requirement is 0.135 mg of folate per 100g of bread.
Folic acid used in fortified foods is a synthetic form called pteroylmonoglutamate. It is in its oxidized state and contains only one conjugated glutamate residue. Folic acid therefore enters via a different carrier system from naturally occurring folate, and this may have different effects on folate binding proteins and its transporters. Folic acid has a higher bioavailability than natural folates and are rapidly absorbed across the intestine, therefore it is important to consider the Dietary Folate Equivalent (DFE) when calculating one's intake. Natural occurring folate is equal to 1 DFE, however 0.6 µg of folic acid is equal to 1 DFE.
Folic acid food fortification became mandatory in Canada in 1998, with the fortification of 150 µg of folic acid per 100 grams of enriched flour and uncooked cereal grains. The purpose of fortification was to decrease the risk of neural tube defects in newborns. It is important to fortify grains because it is a widely eaten food and the neural tube closes in the first four weeks of gestation, often before many women even know they are pregnant. Canada's fortification program has been successful with a decrease of neural tube defects by 19% since its introduction. A seven-province study from 1993 to 2002 showed a reduction of 46% in the overall rate of neural tube defects after folic acid fortification was introduced in Canada. The fortification program was estimated to raise a person’s folic acid intake level by 70–130 µg/day, however an increase of almost double that amount was actually observed. This could be from the fact that many foods are over fortified by 160–175% the predicted value. In addition, much of the elder population take supplements that adds 400 µg to their daily folic acid intake. This is a concern because 70–80% of the population have detectable levels of unmetabolized folic acid in their blood and high intakes can accelerate the growth of preneoplasmic lesions. It is still unknown the amount of folic acid supplementation that might cause harm.
The Association of Bakers and the Green Party have opposed mandatory fortification, describing it as "mass medication". Food Safety Minister Kate Wilkinson reviewed the decision to fortify in July 2009, citing links between overconsumption of folate with cancer . The New Zealand Government is reviewing whether it will continue with the mandatory introduction of folic acid to bread.
The Food Standards Agency has recommended fortification.
In 1996, the United States Food and Drug Administration (FDA) published regulations requiring the addition of folic acid to enriched breads, cereals, flours, corn meals, pastas, rice, and other grain products. This ruling took effect on January 1, 1998, and was specifically targeted to reduce the risk of neural tube birth defects in newborns. There are concerns that the amount of folate added is insufficient . In October 2006, the Australian press claimed that U.S. regulations requiring fortification of grain products were being interpreted as disallowing fortification in non-grain products, specifically Vegemite (an Australian yeast extract containing folate). The FDA later said the report was inaccurate, and no ban or other action was being taken against Vegemite.
As a result of the folic acid fortification program, fortified foods have become a major source of folic acid in the American diet. The Centers for Disease Control and Prevention in Atlanta, Georgia used data from 23 birth defect registries covering about half of United States births, and extrapolated their findings to the rest of the country. These data indicate since the addition of folic acid in grain-based foods as mandated by the FDA, the rate of neural tube defects dropped by 25% in the United States. The results of folic acid fortification on the rate of neural tube defects in Canada have also been positive, showing a 46% reduction in prevalence of NTDs; the magnitude of reduction was proportional to the prefortification rate of NTDs, essentially removing geographical variations in rates of NTDs seen in Canada before fortification.
When the U.S. Food and Drug Administration set the folic acid fortification regulation in 1996, the projected increase in folic acid intake was 100 µg/d. Data from a study with 1480 subjects showed that folic acid intake increased by 190 µg/d and total folate intake increased by 323 µg dietary folate equivalents (DFE)/d. Folic acid intake above the upper tolerable intake level (1000 µg folic acid/d) increased only among those individuals consuming folic acid supplements as well as folic acid found in fortified grain products. Taken together, folic acid fortification has led to a bigger increase in folic acid intake than first projected.
;Biochemistry links
Category:Dietary supplements * Category:Dicarboxylic acids Category:B vitamins Category:Alcohols
ar:حمض الفوليك bs:Folna kiselina bg:Фолиева киселина ca:Àcid fòlic cs:Kyselina listová cy:Asid Ffolig da:Folsyre de:Folsäure dv:ވިޓަމިން ބީ9 et:Foolhape es:Ácido fólico eo:Foliata acido eu:Azido foliko fa:ویتامین ب۹ fr:Vitamine B9 ko:폴산 hi:फोलिक एसिड hr:Vitamin B9 id:Asam folat is:Fólínsýra it:Acido folico he:חומצה פולית lb:Folsaier lt:Folio rūgštis hu:Folsav mk:Фолна киселина nl:Foliumzuur ja:葉酸 no:Folsyre oc:Vitamina B9 pl:Kwas foliowy pt:Ácido fólico ro:Acid folic ru:Фолиевая кислота sq:Acidi folik simple:Folic acid sk:Kyselina listová sl:Folna kislina sr:Folna kiselina sh:Vitamin B9 fi:Foolihappo sv:Folsyra ta:இலைக்காடி te:ఫోలిక్ ఆమ్లం th:กรดโฟลิก tr:Folik asit uk:Фолієва кислота ur:فولک تیزاب vi:Axít folic zh:叶酸This text is licensed under the Creative Commons CC-BY-SA License. This text was originally published on Wikipedia and was developed by the Wikipedia community.
The World News (WN) Network, has created this privacy statement in order to demonstrate our firm commitment to user privacy. The following discloses our information gathering and dissemination practices for wn.com, as well as e-mail newsletters.
We do not collect personally identifiable information about you, except when you provide it to us. For example, if you submit an inquiry to us or sign up for our newsletter, you may be asked to provide certain information such as your contact details (name, e-mail address, mailing address, etc.).
When you submit your personally identifiable information through wn.com, you are giving your consent to the collection, use and disclosure of your personal information as set forth in this Privacy Policy. If you would prefer that we not collect any personally identifiable information from you, please do not provide us with any such information. We will not sell or rent your personally identifiable information to third parties without your consent, except as otherwise disclosed in this Privacy Policy.
Except as otherwise disclosed in this Privacy Policy, we will use the information you provide us only for the purpose of responding to your inquiry or in connection with the service for which you provided such information. We may forward your contact information and inquiry to our affiliates and other divisions of our company that we feel can best address your inquiry or provide you with the requested service. We may also use the information you provide in aggregate form for internal business purposes, such as generating statistics and developing marketing plans. We may share or transfer such non-personally identifiable information with or to our affiliates, licensees, agents and partners.
We may retain other companies and individuals to perform functions on our behalf. Such third parties may be provided with access to personally identifiable information needed to perform their functions, but may not use such information for any other purpose.
In addition, we may disclose any information, including personally identifiable information, we deem necessary, in our sole discretion, to comply with any applicable law, regulation, legal proceeding or governmental request.
We do not want you to receive unwanted e-mail from us. We try to make it easy to opt-out of any service you have asked to receive. If you sign-up to our e-mail newsletters we do not sell, exchange or give your e-mail address to a third party.
E-mail addresses are collected via the wn.com web site. Users have to physically opt-in to receive the wn.com newsletter and a verification e-mail is sent. wn.com is clearly and conspicuously named at the point of
collection.If you no longer wish to receive our newsletter and promotional communications, you may opt-out of receiving them by following the instructions included in each newsletter or communication or by e-mailing us at michaelw(at)wn.com
The security of your personal information is important to us. We follow generally accepted industry standards to protect the personal information submitted to us, both during registration and once we receive it. No method of transmission over the Internet, or method of electronic storage, is 100 percent secure, however. Therefore, though we strive to use commercially acceptable means to protect your personal information, we cannot guarantee its absolute security.
If we decide to change our e-mail practices, we will post those changes to this privacy statement, the homepage, and other places we think appropriate so that you are aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it.
If we make material changes to our e-mail practices, we will notify you here, by e-mail, and by means of a notice on our home page.
The advertising banners and other forms of advertising appearing on this Web site are sometimes delivered to you, on our behalf, by a third party. In the course of serving advertisements to this site, the third party may place or recognize a unique cookie on your browser. For more information on cookies, you can visit www.cookiecentral.com.
As we continue to develop our business, we might sell certain aspects of our entities or assets. In such transactions, user information, including personally identifiable information, generally is one of the transferred business assets, and by submitting your personal information on Wn.com you agree that your data may be transferred to such parties in these circumstances.